Assessing the benefit: Risk ratio of a drug - randomized and naturalistic evidence

Dialogues in Clinical Neuroscience

Volumn 13, Issue 2, 2011, Pages 183-190

  Curtin, François ^a  

^a GENEURO SA   (Switzerland)

Author keywords

Benefit risk; Benefit:risk ratio; Bra; Drug development; Efficacy; Safety

Indexed keywords

ADVERSE OUTCOME; ARTICLE; CLINICAL RESEARCH; DRUG EFFICACY; DRUG INTOXICATION; DRUG LEGISLATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPE; FOOD AND DRUG ADMINISTRATION; HUMAN; NATURALISTIC INQUIRY; NEUROSCIENCE; NONHUMAN; PHARMACOEPIDEMIOLOGY; PLACEBO EFFECT; QUALITATIVE ANALYSIS; QUALITY ADJUSTED LIFE YEAR; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; METHODOLOGY; REVIEW; RISK; RISK ASSESSMENT;

HUMANS; ODDS RATIO; PHARMACOEPIDEMIOLOGY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK ASSESSMENT;

EID: 80052179489     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Talele TT, Khedkar SA, Rigby AC Successful applications of computer aided drug discovery: moving drugs from concept to the clinic. Curr Top Med Chem. 2010;10:127-141.
2. Schnur DM Recent trends in library design: 'rational design' revisited. Curr Opin Drug Discov Devel. 2008;11:375-380.
3. Cavero I Exploratory safety pharmacology: a new safety paradigm to de-risk drug candidates prior to selection for regulatory science investigations. Exp Opin Drug Saf. 2009;8:627-647.
4. Food and Drug Administration. News Release on Vioxx withdrawal. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108361.htm. 2004.
5. Schuler U, Ehninger G Thalidomide: rationale for renewed use in immunological disorders. Drug Saf. 1995;12:364-369.
6. Medterms - Online Dictionary of Medical Terms. Available at: http://www.medterms.com.
7. Pocock SJ Clinical Trials, a Practical Approach. Chichester, UK: John Wiley and Sons 1984
8. Hill AB Statistical Methods in Clinical and Preventive Medicine. Edinburgh, UK: Livingstone 1962
9. Food and Drug Administration: Guidance for Industry. Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. 1998
10. Lehrer J The truth wears off. Is there something wrong with the scientific method? The New Yorker. 2010:52-57.
11. Hoffman DE Annals of science: going viral. The New Yorker. 2011:26.
12. European Medicines Agency. Note for guidance on the clinical evaluation of QTIQTc interval prolongation and proarrhythmic potential for non-antiarrhytmic drugs. 2005.
13. Strom BL. Pharmacoepidemiology. 2001.
14. Edwards R, Wiholm BE, Martinez C Concepts in risk-benefit assessment. a simple merit analysis of a medicine. Drug Saf. 1996;15:1-7.
15. Giezen TJ, Mantel-Teeuwisse AK, Straus SM, et al. Evaluation of postauthorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval. Drug Saf. 2009;32:1175-1187.
16. Guo JJ, Pandey S, Doyle J, Bian B, Lis Y, Raisch DW A review of quantitative risk-benefit methodologies for assessing drug safety and efficacyreport of the ISPOR Risk Management Working Group. Value In Health. 2010;13:657-666.
17. Laupacis A, Sackettt DL, Roberts RS An assessment of clinically useful measures of the consequences of treatment. N Engl J Med. 1988;318:1728-1733.
18. Willan AR, O'Brien BJ, Cook DJ Benefit-risk ratios in the assessment of the clinical evidence of a new therapy. Control Clin Trials. 1997;18:121-130.
19. Holden WL, Juhaeri J, Dai W Benefit-risk analysis: a proposal using quantitative methods. Pharmacoepidemiology Drug Saf. 2003;12:611-616.
20. Holden WL, Juhaeri J, Dai W Benefit-risk analysis: examples using quantitative methods. Pharmacoepidemiology Drug Saf. 2003;12:693-697.
21. Gelber RD, Goldhirsch A, Cavali F Quality of life adjusted evaluation of adjuvant therapies for operable breast cancer. The international breast cancer study group. Ann Intern Med. 1991;114:621-628.
22. Garrison LP, Towse A, Bresnahan BW Assessing a structured quantitative health outcomes approach to drug risk-benefit analysis. Health Aff. 2007;26:684-695.
23. Mussen F, Salek S, Walker S A quantitative approach to benefit risk assessment of medicines - part 1: the development of a new model using multi-criteria decision analysis. Pharmacoepidemiol Drug Saf. 2007;16:S2-S15.
24. Mussen F, Salek S, Walker S A quantitative approach to benefit risk assessment of medicines - part 2: the practical application of a new model. Pharmacoepidemiol Drug Saf. 2007;16:S16-S41.
25. Beckmann J Basic aspects of risk-benefit analysis. Semin Thromb Hemost. 1999;25:89-95.
26. Food and Drug Administration's Overall Risk Management Activities Available at: http://www.fda.gov/Safety/SafetyofSpecificProducts/ucm180589.htm. 2009.
27. Jenkins J A United States Regulator's Perspective on Risk Benefit Considerations. Available at: http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM210155.pdf. 2010
28. European Medicines Agency. Reflection Paper on Benefit-Risk Assessment Methods in the Context of the Evaluation of Marketing Authorisation Application of Medicinal Products for Human Use. 2008
29. Idanpaan-Heikkila J, Alhava E, Olkinuora M, Palva I Letter: Clozapine and agranulocytosis. Lancet. 1975;2:611.
30. Wasson S, Zafar MN, Best J, Reddy HK Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience. J Cardiovasc Pharmacol Ther. 2006;11:77-83.
31. Haustein UF, Rytter M Methotrexate in psoriasis: 26 years' experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol. 2000;14:382-388.
32. Robboy SJ, Truslow GY, Anton J, Richart RM Role of hormones including diethylstibestrol (DES) in the pathogenesis of cervical and vaginal intraepithelial neoplasia. Gynecol Oncol. 1981;12(2 Pt 2):S98-110.
33. International Conference on Harmonisation. The Extent of Population. Exposure to Assess Clinical Safety: For Drugs Intended for Long-term Treatment of Non-Life-Threatening Conditions. Yokohama, Japan 1995
34. Henschke U, Flehinger BJ Decision theory in cancer therapy. Cancer. 1967;20:1819-1826.